EP0515228A3 - - Google Patents

Download PDF

Info

Publication number
EP0515228A3
EP0515228A3 EP19920304692 EP92304692A EP0515228A3 EP 0515228 A3 EP0515228 A3 EP 0515228A3 EP 19920304692 EP19920304692 EP 19920304692 EP 92304692 A EP92304692 A EP 92304692A EP 0515228 A3 EP0515228 A3 EP 0515228A3
Authority
EP
European Patent Office
Prior art keywords
parathyroid hormone
ultrapure
human parathyroid
absence
obtaining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19920304692
Other versions
EP0515228A2 (en
EP0515228B1 (en
Inventor
Dennis R. Sindrey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire NPS Pharmaceuticals Inc
Original Assignee
Allelix Biopharmaceuticals Inc
Glaxo Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24840399&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0515228(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allelix Biopharmaceuticals Inc, Glaxo Canada Inc filed Critical Allelix Biopharmaceuticals Inc
Publication of EP0515228A2 publication Critical patent/EP0515228A2/en
Publication of EP0515228A3 publication Critical patent/EP0515228A3/xx
Application granted granted Critical
Publication of EP0515228B1 publication Critical patent/EP0515228B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Human parathyroid hormone is provided in an ultrapure form characterized by the absence of protein contaminants detectable by capillary electrophoresis analysis. A method for obtaining such ultrapure human parathyroid hormone is also described.
EP92304692A 1991-05-23 1992-05-22 Essentially pure human parathyroid hormone Expired - Lifetime EP0515228B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/707,114 US5208041A (en) 1991-05-23 1991-05-23 Essentially pure human parathyroid hormone
US707114 1991-05-23

Publications (3)

Publication Number Publication Date
EP0515228A2 EP0515228A2 (en) 1992-11-25
EP0515228A3 true EP0515228A3 (en) 1994-05-04
EP0515228B1 EP0515228B1 (en) 1998-03-25

Family

ID=24840399

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92304692A Expired - Lifetime EP0515228B1 (en) 1991-05-23 1992-05-22 Essentially pure human parathyroid hormone

Country Status (16)

Country Link
US (1) US5208041A (en)
EP (1) EP0515228B1 (en)
JP (1) JP2563726B2 (en)
KR (1) KR970007755B1 (en)
AT (1) ATE164394T1 (en)
CA (1) CA2068438C (en)
DE (1) DE69224858T2 (en)
DK (1) DK0515228T3 (en)
ES (1) ES2115642T3 (en)
FI (1) FI106802B (en)
HK (1) HK1004340A1 (en)
IE (1) IE921672A1 (en)
IL (3) IL101829A (en)
NO (2) NO304190B1 (en)
NZ (1) NZ242855A (en)
ZA (1) ZA923735B (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420242A (en) * 1986-10-22 1995-05-30 Kaare M. Gautvik Production of human parathyroid hormone from microorganisms
USRE37919E1 (en) 1989-05-12 2002-12-03 The General Hospital Corporation Recombinant DNA method for production of parathyroid hormone
TW273513B (en) * 1993-10-27 1996-04-01 Chugai Pharmaceutical Co Ltd
US20020193338A1 (en) * 1994-02-18 2002-12-19 Goldstein Steven A. In vivo gene transfer methods for wound healing
US5942496A (en) 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US5763416A (en) 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
US6074840A (en) 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
CA2297489A1 (en) 1997-07-30 1999-02-11 Emory University Novel bone mineralization proteins, dna, vectors, expression systems
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
AR033639A1 (en) 1998-08-19 2004-01-07 Lilly Co Eli USE OF PARTIROID HORMONES TO PREPARE MEDICINES TO REDUCE THE RISK OF VERTEBRAL OR NON-VERTEBRAL OSEAS FRACTURES IN HUMAN BEINGS WITH RISK OF SUFFERING OR WHO HAVE OSTEOPOROSIS
AU1447600A (en) * 1998-10-22 2000-05-08 Thomas J. Gardella Bioactive peptides and peptide derivatives of parathyroid hormone (pth) and parathyroid hormone-related peptide (pthrp)
WO2000032771A1 (en) * 1998-11-30 2000-06-08 The General Hospital Corporation Pth1r and pth3r receptors, methods and uses thereof
US7820393B2 (en) * 1999-01-14 2010-10-26 Scantibodies Laboratory, Inc. Methods, kits and antibodies for detecting parathyroid hormone
US6689566B1 (en) 1999-01-14 2004-02-10 Scantibodies Laboratory, Inc. Methods, kits, and antibodies for detecting parathyroid hormone
US20080108086A1 (en) * 1999-06-02 2008-05-08 Cantor Thomas L Parathyroid hormone antagonists and uses thereof
US7893021B2 (en) * 1999-06-02 2011-02-22 Scantibodies Laboratory, Inc. Parathyroid hormone antagonists and uses thereof
WO2001023521A2 (en) * 1999-09-29 2001-04-05 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
CA2414966A1 (en) * 2000-06-30 2002-01-10 Suntory Limited A pharmaceutical component based on human parathyroid hormone and a pharmaceutical composition for intranasal administration containing the component
US6905886B2 (en) * 2000-08-11 2005-06-14 Quest Diagnostics Investments Incorporated Preservative solutions
US6387711B1 (en) * 2000-08-11 2002-05-14 Quest Diagnostics Investments Incorporated Liquid intact parathyroid hormone (PTH) standards
AU2002339843B2 (en) * 2001-07-23 2007-12-06 The General Hospital Corporation Conformationally constrained parathyroid hormone (PTH) analogs
US20040067526A1 (en) * 2002-10-03 2004-04-08 Cantor Thomas L. Methods for diagnosing and guiding treatment of bone turnover disease
AU2003220380A1 (en) * 2003-03-19 2004-11-19 Bristol-Myers Squibb Company CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH Alpha-HELIX STABILIZERS
KR100540659B1 (en) * 2003-07-02 2006-01-10 삼성전자주식회사 Method and apparatus for printing enlarged image, and computer-readable recording media for storing computer program
EP1653985A4 (en) 2003-07-17 2009-08-05 Gen Hospital Corp Conformationally constrained parathyroid hormone (pth) analogs
WO2005112984A2 (en) * 2004-05-13 2005-12-01 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US7541140B2 (en) * 2004-06-03 2009-06-02 Scantibodies Laboratory, Inc. Assessing risk for kidney stones using parathyroid hormone agonist and antagonist
EP1945245A2 (en) * 2005-11-10 2008-07-23 The Board of Control of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
EP2054077A4 (en) * 2006-08-04 2010-10-13 Gen Hospital Corp Polypeptide derivatives of parathyroid hormone (pth)
CA3017668C (en) * 2007-08-01 2021-11-09 The General Hospital Corporation Screening methods using g-protein coupled receptors and related compositions
CA2694562A1 (en) * 2007-08-09 2009-02-12 Usv Limited Novel orthogonal process for purification of recombinant human parathyroid hormone (rhpth) (1-34)
BR112012002934B1 (en) * 2009-08-11 2021-12-21 Biocon Limited CHROMATOGRAPHIC PROCESSES AND THEIR PURIFIED COMPOUNDS
AU2009356227A1 (en) 2009-12-07 2012-06-21 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9492508B2 (en) 2010-05-13 2016-11-15 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
CN104645318B (en) * 2011-06-07 2021-11-02 旭化成制药株式会社 High-purity freeze-dried preparation containing PTH and process for producing the same
CN102993293B (en) * 2012-12-05 2014-05-07 深圳翰宇药业股份有限公司 Method for purifying teriparatide acetate
LU100168B1 (en) 2017-04-12 2018-10-15 Michael Pazianas Prevention of Bone and Mineral Disorders by Restoring Calcium and Phosphate Homeostasis in Patients Suffering from Chronic Kidney Disease
EP4110370A4 (en) 2020-03-30 2023-06-07 Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. Formulations of human parathyroid hormone (pth) and methods for producing same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0357391A2 (en) * 1988-08-31 1990-03-07 Allelix Biopharmaceuticals Inc. Excretion of heterologous proteins from E. Coli
WO1991005050A1 (en) * 1989-09-29 1991-04-18 Her Majesty In Right Of Canada As Represented By The National Research Council Of Canada Synthesis of mature human parathyroid hormone

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886132A (en) * 1972-12-21 1975-05-27 Us Health Human parathyroid hormone

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0357391A2 (en) * 1988-08-31 1990-03-07 Allelix Biopharmaceuticals Inc. Excretion of heterologous proteins from E. Coli
WO1991005050A1 (en) * 1989-09-29 1991-04-18 Her Majesty In Right Of Canada As Represented By The National Research Council Of Canada Synthesis of mature human parathyroid hormone

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
M.T.W. HEARN: "reversed-phase high performance liquid chromatography", METHODS IN ENZYMOLOGY, vol. 104, 1984, ACADEMIC PRESS , INC., pages 190 - 212 *
P. M. YOUNG ET AL: "Optimization of high-performance liquid chromatographic peptide separations with alternative mobile and stationary phases", JOURNAL OF CHROMATOGRAPHY, vol. 512, 1990, AMSTERDAM NL, pages 273 - 281 *
S.A. RABBANI ET AL: "Recombinant human parathyroid hormone synthesized in E.coli", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 263, no. 3, 25 January 1988 (1988-01-25), BALTIMORE, MD US, pages 1307 - 1313 *
TERUTOSHI KIMURA ET AL: "Solution synthesis of (ASN76)-human parathyroid hormone(1-84)", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 114, no. 2, 29 July 1983 (1983-07-29), DULUTH, MINNESOTA US, pages 493 - 499 *
U. JUERGENS: "Alkylamine / phosphoric acid as a universal buffer system for basic and acidic mobile phases in HPLC", JOURNAL OF LIQUID CHROMATOGRAPHY, vol. 11, no. 9&10, 1988, pages 1925 - 1940 *

Also Published As

Publication number Publication date
EP0515228A2 (en) 1992-11-25
ATE164394T1 (en) 1998-04-15
IL101829A0 (en) 1992-12-30
NO2006013I1 (en) 2006-11-06
DE69224858T2 (en) 1998-07-23
CA2068438C (en) 1996-11-12
IE921672A1 (en) 1992-12-02
KR970007755B1 (en) 1997-05-16
DK0515228T3 (en) 1998-09-28
AU639856B2 (en) 1993-08-05
NO922000L (en) 1992-11-24
IL101829A (en) 1999-12-31
ZA923735B (en) 1993-01-27
FI922356A (en) 1992-11-24
AU1604992A (en) 1993-03-11
HK1004340A1 (en) 1998-11-20
ES2115642T3 (en) 1998-07-01
NO304190B1 (en) 1998-11-09
US5208041A (en) 1993-05-04
NO2006013I2 (en) 2009-12-07
EP0515228B1 (en) 1998-03-25
FI922356A0 (en) 1992-05-22
DE69224858D1 (en) 1998-04-30
IL119840A0 (en) 1997-03-18
NZ242855A (en) 1994-04-27
FI106802B (en) 2001-04-12
JPH0687897A (en) 1994-03-29
CA2068438A1 (en) 1992-11-24
JP2563726B2 (en) 1996-12-18
NO922000D0 (en) 1992-05-21
IL119840A (en) 2005-08-31

Similar Documents

Publication Publication Date Title
EP0515228A3 (en)
DE3876273D1 (en) ISOELECTRIC FOCUSING METHOD AND DEVICE FOR CARRYING OUT THIS METHOD.
DE69405102D1 (en) Antikoerperfragmente in therapie
DE3680997D1 (en) DEVICE FOR FEEDBACK FEEDBACK.
DE3682249D1 (en) METHOD FOR IMAGE PROCESSING AND DEVICE FOR IMAGE GENERATION.
JPS57171999A (en) Ox pre-growth and growth hormone
ZA888823B (en) Automated capillary electrophoresis apparatus
EP0213105A3 (en) Method for assembling an optoisolator and leadframe therefor
DE3683394D1 (en) PROCESSING METHOD AND DEVICE FOR MACHINE TRANSLATION.
DE69327928D1 (en) Device for coding still images
EP0259816A3 (en) Method for bonding semiconductor laser element and apparatus therefor
EP0168030A3 (en) Contact type image sensor and driving method therefor
EP0181009A3 (en) Image processing device and method for controlling the same
DE3778483D1 (en) DEVICE FOR LINEAR BEARINGS WITH COMPLETE REALIZATION AND CORRESPONDING METHOD.
EP0196405A3 (en) Color picture reader and method for operating the same
AU5738286A (en) Lorgnette frame
IT8467198A1 (en) METHOD AND DEVICE FOR THE CONTROL OF THE WELDING PROCESSES BY ANALYSIS OF THE BRIGHTNESS GENERATED DURING THE PROCESS.
HU900822D0 (en) Trichoderma-fungus and fungicid containing it
GB2174916B (en) Liquid-vapour contact method and apparatus
EP0205726A3 (en) Image controlling method and device for carrying out the same
GB2181256B (en) Method for controlling an oxygen concentration sensing device
EP0222921A4 (en) Apparatus for preventing pulsating current for liquid chromatography and method therefor.
FR2653560B2 (en) AUTOMATIC ELECTROPHORESIS METHOD AND APPARATUS.
EP0613002A3 (en) Method and apparatus for taking and preparing samples for capillary electrophoresis.
DE69126519D1 (en) Capillary electrophoresis method and device therefor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL PT SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 19941019

17Q First examination report despatched

Effective date: 19960219

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ASTRA AKTIEBOLAG

Owner name: GLAXO CANADA INC.

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ASTRA AKTIEBOLAG

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL PT SE

REF Corresponds to:

Ref document number: 164394

Country of ref document: AT

Date of ref document: 19980415

Kind code of ref document: T

ITF It: translation for a ep patent filed

Owner name: JACOBACCI & PERANI S.P.A.

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

ET Fr: translation filed
GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

REF Corresponds to:

Ref document number: 69224858

Country of ref document: DE

Date of ref document: 19980430

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2115642

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 19980406

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: NPS ALLELIX CORP.

Free format text: ASTRA AKTIEBOLAG##151 85 SOEDERTAELJE (SE) -TRANSFER TO- NPS ALLELIX CORP.#6850 GOREWAY DRIVE#MISSISSAUGA, ONTARIO L4V 1V7 (CA)

Ref country code: CH

Ref legal event code: NV

Representative=s name: PATENTANWAELTE SCHAAD, BALASS, MENZL & PARTNER AG

NLS Nl: assignments of ep-patents

Owner name: NPS ALLELIX CORP.

Effective date: 20051025

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

REG Reference to a national code

Ref country code: DK

Ref legal event code: CTFF

Spc suppl protection certif: CA 2006 00028

Filing date: 20061020

Expiry date: 20170522

REG Reference to a national code

Ref country code: PT

Ref legal event code: TE4A

Owner name: NPS ALLELIX CORP., CA

Effective date: 20070907

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: SCHNEIDER FELDMANN AG PATENT- UND MARKENANWAELTE

Ref country code: CH

Ref legal event code: PFA

Owner name: NPS ALLELIX CORP.

Free format text: NPS ALLELIX CORP.#6850 GOREWAY DRIVE#MISSISSAUGA, ONTARIO L4V 1V7 (CA) -TRANSFER TO- NPS ALLELIX CORP.#C/O BLAKE, CASSELS & GRAYDON LLP 199 BAY STREET SUITE 2800, COMMERCE COURT WEST#TORONTO, ON M5L 1A9 (CA)

REG Reference to a national code

Ref country code: FR

Ref legal event code: CA

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

BECA Be: change of holder's address

Owner name: *NPS ALLELIX CORP.C/O BLAKE, CASSELS & GRAYDON LLP

Effective date: 20051020

REG Reference to a national code

Ref country code: FR

Ref legal event code: AU

Ref country code: FR

Ref legal event code: GC

REG Reference to a national code

Ref country code: DK

Ref legal event code: CTFG

Free format text: PRODUCT NAME: HUMANT PARATHYREOIDEAHORMON

Spc suppl protection certif: CA 2006 00028

Filing date: 20061020

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: NPS PHARMACEUTICALS, INC.

Free format text: NPS ALLELIX CORP.#C/O BLAKE, CASSELS & GRAYDON LLP 199 BAY STREET SUITE 2800, COMMERCE COURT WEST#TORONTO, ON M5L 1A9 (CA) -TRANSFER TO- NPS PHARMACEUTICALS, INC.#550 HILLS DRIVE 3RD FLOOR#BEDMINSTER, NJ 07921 (US)

NLS Nl: assignments of ep-patents

Owner name: NPS PHARMACEUTICALS, INC.

Effective date: 20080818

REG Reference to a national code

Ref country code: PT

Ref legal event code: PC4A

Owner name: NPS PHARMACEUTICALS, INC., US

Effective date: 20081024

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20100304 AND 20100310

REG Reference to a national code

Ref country code: FR

Ref legal event code: ER

Ref country code: FR

Ref legal event code: AU

REG Reference to a national code

Ref country code: FR

Ref legal event code: AU

Ref country code: FR

Ref legal event code: TP

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20100923 AND 20100929

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20110523

Year of fee payment: 20

Ref country code: ES

Payment date: 20110524

Year of fee payment: 20

Ref country code: SE

Payment date: 20110503

Year of fee payment: 20

Ref country code: LU

Payment date: 20110525

Year of fee payment: 20

Ref country code: GR

Payment date: 20110525

Year of fee payment: 20

Ref country code: FR

Payment date: 20110511

Year of fee payment: 20

Ref country code: CH

Payment date: 20110428

Year of fee payment: 20

Ref country code: PT

Payment date: 20110511

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20110429

Year of fee payment: 20

Ref country code: NL

Payment date: 20110524

Year of fee payment: 20

Ref country code: BE

Payment date: 20110525

Year of fee payment: 20

Ref country code: GB

Payment date: 20110531

Year of fee payment: 20

Ref country code: DK

Payment date: 20110525

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20110526

Year of fee payment: 20

Ref country code: IT

Payment date: 20110527

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69224858

Country of ref document: DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69224858

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: V4

Effective date: 20120522

Ref country code: PT

Ref legal event code: MM4A

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20120522

BE20 Be: patent expired

Owner name: NPS PHARMACEUTICALS INC.

Effective date: 20120522

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20120521

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: GR

Ref legal event code: MA

Ref document number: 980401331

Country of ref document: GR

Effective date: 20120523

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20120530

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20120521

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 164394

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120522

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20121207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20120523

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20120523